- Home
- PALI vs APM Comparison
PALI vs APM Comparison
Compare PALI & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PALI
- APM
- Stock Information
- Founded
- PALI 1996
- APM 2010
- Country
- PALI United States
- APM United Kingdom
- Employees
- PALI N/A
- APM N/A
- Industry
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- PALI Health Care
- APM Health Care
- Exchange
- PALI Nasdaq
- APM Nasdaq
- Market Cap
- PALI 3.5M
- APM 4.0M
- IPO Year
- PALI N/A
- APM 2018
- Fundamental
- Price
- PALI $1.75
- APM $0.76
- Analyst Decision
- PALI Strong Buy
- APM
- Analyst Count
- PALI 2
- APM 0
- Target Price
- PALI $23.00
- APM N/A
- AVG Volume (30 Days)
- PALI 3.7M
- APM 55.6K
- Earning Date
- PALI 11-12-2024
- APM 12-27-2024
- Dividend Yield
- PALI N/A
- APM N/A
- EPS Growth
- PALI N/A
- APM N/A
- EPS
- PALI N/A
- APM N/A
- Revenue
- PALI N/A
- APM $431,378.00
- Revenue This Year
- PALI N/A
- APM $157,729.10
- Revenue Next Year
- PALI N/A
- APM N/A
- P/E Ratio
- PALI N/A
- APM N/A
- Revenue Growth
- PALI N/A
- APM N/A
- 52 Week Low
- PALI $1.38
- APM $0.46
- 52 Week High
- PALI $22.35
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- PALI 40.97
- APM 40.52
- Support Level
- PALI $1.59
- APM $0.73
- Resistance Level
- PALI $2.20
- APM $0.78
- Average True Range (ATR)
- PALI 0.39
- APM 0.09
- MACD
- PALI 0.02
- APM 0.04
- Stochastic Oscillator
- PALI 19.27
- APM 59.96
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.